|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Of the 108 men with PSA level ≥3.0 ng/mL and a referral related to PCa, GPs were advised to refer 58 men to the urologist (54%).
|
29594017 |
2018 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
We found no evidence that either circulating 25(OH)D, 1,25(OH)2D, or vitamin D pathway polymorphisms were associated with PSA doubling time in men undergoing active monitoring for localized prostate cancer.
|
22955340 |
2013 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Assuming haematogenous prostate tissue-specific mRNA species to be representative for the presence of circulating prostate cancer cells, an impressive series of clinical studies, for the greater part addressing mRNA encoding for prostate-specific antigen (PSA), were performed to improve pre-operative staging (molecular staging) and prognosis of prostate cancer, and to study iatrogenic cell dissemination.
|
15703810 |
2005 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
We assessed the predictive value of TP53 mutations and prostate-specific antigen (PSA) for tumor progression in prostate cancer (PCa) patients.
|
20592345 |
2010 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Study Finds Overall Prostate Cancer Mortality Decreases with PSA Screening.
|
29189229 |
2017 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Analyses were restricted to 2007 patients who harbored low-risk PCa at ≥10-cores initial biopsy according to D'Amico classification (PSA <10.0 ng/ml, Gleason score <7 and clinical stage ≤T2a).
|
27289238 |
2017 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Data were from REDUCE, which tested dutasteride 0.5 mg daily for PCa risk reduction in men with PSA 2.5-10.0 ng mL(-1) and a negative prestudy biopsy.
|
22211699 |
2012 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
However, we found a significant influence of the ARE-I PSA polymorphism on prostate cancer risk, when calculating the combination of the A/G and G/G genotypes relative to subjects with the A/A genotype (OR = 0.63; 95% CL 0.39-0.99; P = 0.048), suggesting that the G allele has a protective effect.
|
12376473 |
2002 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
We recently reported an association between prostate cancer risk and polymorphisms in the prostate-specific antigen (PSA) and androgen receptor (AR) genes.
|
11401905 |
2001 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Influence of cytokine gene polymorphisms on prostate-specific antigen recurrence in prostate cancer after radical prostatectomy.
|
19996656 |
2009 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Screening for prostate cancer in the general population using transrectal ultrasonography, digital rectal examination and/or prostate acid phosphatase began in Japan in the early 1980s, and screening with prostate-specific antigen and digital rectal examination has been widespread in the USA since the late 1980s.
|
31183923 |
2019 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.
|
16806661 |
2007 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Our study did not provide support for the hypothesized relationship between CYP17 and PSA gene polymorphisms and prostate cancer in the Slovak male population.
|
22528335 |
2012 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Prostate-specific antigen and 17-hydroxylase polymorphic genotypes in patients with prostate cancer and benign prostatic hyperplasia.
|
17961073 |
2007 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The rs61752561 in KLK3 and rs2735839 in the KLK2-KLK3 intergenic region were strongly associated with prostate cancer-specific survival, and rs10486567 in the 7JAZF1 gene were associated with biochemical recurrence.
|
20460480 |
2010 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The association of polymorphic variants with prostate specific antigen failure in patients with prostate cancer was analyzed by Kaplan-Meier curves.
|
19237173 |
2009 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The expressed ARf enhanced the PP activity by about 110-fold in the PSA-producing prostate cancer cell line, LNCaP, under low testosterone concentrations.
|
11245419 |
2001 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
We identified and analysed outcomes of all RPs performed for high-risk prostate cancer (clinical stage >T2 and/or biopsy Gleason grade >7 and/or preoperative prostate-specific antigen level ≥20 ng/mL) in the national registry for 2014 and 2015.
|
30681267 |
2019 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Despite the use of prostate specific antigen (PSA), Gleason-score, and T-category as prognostic factors, up to 40% of patients with intermediate-risk prostate cancer will fail radical prostatectomy or precision image-guided radiotherapy (IGRT).
|
22048240 |
2012 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Vitamin D receptor genetic polymorphisms are associated with PSA level, Gleason score and prostate cancer risk in African-American men.
|
25750310 |
2015 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
But six of the hotspot subjects had PSA levels >3ng/mL, 3 of whom were suspected to have prostate cancer (PC) after digital rectal examination.
|
28412653 |
2017 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Prostate cancer in 432 men aged <50 years in the prostate-specific antigen era: a new outlook.
|
30303599 |
2018 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The present study aimed to investigate the diagnostic efficacy and the regional location of prostate cancer (PCa) as well as the accuracy of assessment between trans-perineal template-guided mapping biopsy (TTMB) and freehand trans-perineal biopsy (FTPB) for men with PSA < 20 ng/ml.
|
31448239 |
2019 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
After 7,254 person-years of follow-up, and adjusting for clinical stage, prostate-specific antigen, Gleason score, and treatment, BRCA2 and BRCA1 mutation carriers had a higher risk of recurrence [HR (95% CI), 2.41 (1.23-4.75) and 4.32 (1.31-13.62), respectively] and prostate cancer-specific death [HR (95% CI), 5.48 (2.03-14.79) and 5.16 (1.09-24.53), respectively] than noncarriers.
|
20215531 |
2010 |
|
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The presence of short AR alleles and the G allele of the PSA gene may contribute to the development of prostate cancer in a 47,XXY patient.
|
15350307 |
2004 |